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Letrozole, an aromatase inhibitor, has been demonstrated to be eﬀective as an ovulation induction and controlled ovarian
hyperstimulation agent. However, dose administration has generally been limited to 5 days at 2.5 to 7.5mg daily. We undertook a
retrospectivereviewofover900treatmentcyclesusingletrozoleindosesashighas12.5mgperday.Resultsindicatethatsuchdoses
do indeed oﬀer beneﬁt to patients; in that there is increased follicular growth and a higher number of predicted ovulations with
higher doses of the drug. However, increasing doses does not produce a detrimental eﬀect upon endometrial thickness. High-dose
letrozole may be of value in women who fail to respond adequately to lower doses. Furthermore, randomized trials are needed to
determine whether high-dose letrozole might actually be optimal as a starting dose for certain treatment groups.
1.Introduction
In women undergoing ovulation induction for the treatment
of oligoanovulation, clomiphene citrate has long been the
initial drug of choice for ﬁrst-line therapy [1]. The drug
works primarily by competitively inhibiting the binding
of estradiol to its receptor in the hypothalamus, thereby
releasing the hypothalamus from negative inhibition and
allowing increased release of follicle stimulating hormone
(FSH) from the pituitary gland. This increase in FSH re-
lease enhances follicular growth, increasing the chances of
ovulation. The drug has also proven useful for producing
multiple ovulation in couples with unexplained infertility,
male factor infertility, and other disorders where controlled
ovarian hyperstimulation has been deemed of value.
WhileapprovedforuseintheUnitedStatesformorethan
40 years, clomiphene has some signiﬁcant limitations. First,
only 75–80% of anovulatory women respond to the medi-
cation with appropriate follicular growth [1]. Furthermore,
side eﬀects of the drug can be psychologically diﬃcult to
endure (hot ﬂashes and mood swings) and detrimental to
fertility (impaired endometrial development and abnormal
cervical secretions). The drug has a lengthy half-life, and
adverse eﬀects may be cumulative over time [2].
A class of drugs known as aromatase inhibitors also has
the potential to enhance FSH release, not by the inhibit-
ing estradiol-receptor interaction, but rather by inhibition
of estradiol synthesis. One such inhibitor, letrozole, was
approved for use in 1997 for the treatment of breast cancer.
By 2001, it had been used in anovulatory women with great
success, and at present the drug is extremely popular among
physicians and patients in the treatment of both ovulation
dysfunction and for controlled ovarian hyperstimulation:
the drug has a half-life of only 45 hours, and side eﬀects,
while similar to those of clomiphene, are far milder and less
frequent [3].
The original choice of dosing with letrozole was extrap-
olated from several studies performed on postmenopausal
women being treated for breast cancer [4, 5]. Data derived
from these patients suggested substantial inhibition of es-
tradiol formation with doses of 2.5–5mg daily. However, the
application of these data to short-term use of the drug in
reproductive age women is highly questionable. Neverthe-
less, clinical investigation of the drug in infertile women has
been generally limited to 5 days of treatment at doses of 2.5–
7.5mg daily.
For several years, we have, in women felt to be subop-
timally responding to established doses of letrozole, admin-2 ISRN Obstetrics and Gynecology
istereddosesofthedrugupto12.5mgdaily.Thismanuscript
was designed to examine the following questions: (1) is
there a role for the use of high doses (greater than 7.5 mg
daily) of letrozole in the treatment of chronic anovulatory
patients?; (2) is there a role for the use of high-dose letrozole
in controlled ovarian hyperstimulation?; (3) what eﬀect does
higher-dose letrozole have upon endometrial development?
2.MaterialsandMethods
This study is a retrospective cohort analysis with data
extracted from our electronic medical record (eIVF, Practice
Highway, Dallas). All patients treated with letrozole and
intrauterine insemination at the Wisconsin Fertility Institute
(Middleton, WI USA), from January, 2007, to December,
2009, were included in the study. Ages ranged from 23 to
47 years. All patients were administered 5 days of a ﬁxed
dose of letrozole beginning day 3 of their cycle; if the patient
was anovulatory, medroxyprogesterone was administered to
inducemenses.Ultrasonographywasperformedoncycleday
11, and follicular number, follicular size, and endometrial
thickness and pattern were determined; follicles were mea-
sured in two perpendicular dimensions and the mean value
recorded, while endometrial thickness was measured at the
point of greatest thickness.
Predicted ovulation number was calculated based upon
the size of follicles on day 11, with a 1.7mm per day adjusted
increase until the day of triggering ovulation with human
chorionic gonadotropin (hGG) [6]. Each extrapolated fol-
licle size was then assigned a probability of ovulation taken
from previously published data [7]. Summation of these
probabilitiesyieldedasinglepredictedovulationnumberper
cycle.
Descriptive statistics were calculated for all variables in
an univariate manner. Multivariate linear and logistic re-
gression analysis were performed to determine the relative
importance of each predictor variable and its covariates.
Terms remained in the equation as signiﬁcant if P<
0.15. Eigen-value diagnostics were performed to identify
potential problems with multicollinearity. One-way analysis
of variance was performed as needed. Data were analyzed
using the Statistical Package for the Social Sciences (SPSS)
program.
3. Results
A total of 907 treatment cycles utilizing a ﬁve-day ﬁxed
dose of letrozole were identiﬁed in the two-year period. Of
these, 41 (4.4%) were eliminated from the analysis due to
abnormalities of medication administration/compliance or
the absence of key information for one or more variables. Of
the 866 remaining cycles, 33 were administered 5mg daily,
80 were given 7.5mg daily, 18 cycles utilized 10mg daily,
and 735 cycles used 12.5mg daily. Results can be seen in
Table 1. For all cycles, the number of predicted ovulations
wassigniﬁcantlylessfordosesof7.5mg/dayorlesscompared
to doses of 10mg/day or more (P<0.001). This remained
true when the data were ﬁltered to include only ﬁrst cycles
Table 1: Ovulations and pregnancy rate for all subjects.
(a) All cycles
Dose (mg) N Predicted ovulation
number (95% CI)
Pregnancy rate
(95% CI)
5 33 1.60 (1.32–1.89) 0.15 (0.02–0.28)
7.5 80 1.69 (1.50–1.89) 0.14 (0.06–0.21)
10 18 2.25 (1.17–2.79) 0.11 (0–0.27)
12.5 735 2.16 (2.09–2.23) 0.07 (0.06–0.09)
(b) First cycle at indicated dose
Dose (mg) N Predicted ovulation
number (95% CI)
Pregnancy rate
(95% CI)
5 28 1.56 (1.25–1.87) 0.19 (0.03–0.35)
7.5 53 1.62 (1.39–1.85) 0.12 (0.03–0.21)
10 10 2.08 (1.30–2.87) 0
12.5 260 1.91 (1.80–2.02) 0.08 (0.05–0.12)
Table 2: Ovulations and pregnancy rate by diagnosis with letrozole
12.5mg daily.
Diagnosis Predicted ovulation
number (95% CI)
Pregnancy rate
(95% CI)
Ovulation
dysfunction 1.88 (1.56–2.20) 0.11 (0.07–0.15)
Other 2.03 (1.82–2.24) 0.06 (0.04–0.08)
on a given dose (P = 0.033). No signiﬁcant diﬀerences were
seen for pregnancy rates among doses.
3.1. High-Dose-Letrozole. As the 12.5mg/day group was
by far the largest, and due to the absence of literature
addressing this dosage, univariate analysis was performed
for this group. The overall mean for predicted ovulation
number was 2.16 per cycle. The data were then ﬁltered
to remove nonindependent trials; analysis of only the ﬁrst
12.5mg dose for a given patient resulted in a mean predicted
ovulation number of 1.91. Both data sets were analyzed for
normality with no indication to reject the null hypothesis of
the data being normally distributed (data not shown). Linear
regression was then performed to determine if this value
was altered signiﬁcantly by age, BMI, or day-3 serum FSH
level. Increasing BMI was signiﬁcantly related to a decrease
in predicted ovulation number for all 12.5mg/day cycles
(P = 0.002)andﬁrst12.5mg/daycycles(P<0.001).Noneof
the other variables had signiﬁcant impact upon the outcome.
The pregnancy rate for the 12.5mg/day dose was 55/735
(7.5%). Logistic regression revealed that a diagnosis of
anovulation resulted in a signiﬁcantly higher pregnancy rate
than other diagnoses (P = 0.003). Age, too, was signiﬁcantly
associated; increasing age lowered the pregnancy rate (P =
0.033).
The mean endometrial thickness on day 11 for all
12.5mg/day cycles was 8.36mm. All patients with more than
one cycle at this dose were then identiﬁed, and the ﬁrst andISRN Obstetrics and Gynecology 3
Table 3: Matched pair analysis.
Dose comparison Endometrial thickness mean
diﬀerence (mm) (95% CI) P value Predicted ovulation number
mean diﬀerence (95% CI) P value
5.0 versus 12.5 0.47 (−0.51–1.45) 0.33 −0.58 (−1.30–0.14) 0.11
7.5 versus 12.5 0.24 (−0.47–0.96) 0.49 −0.72 (−1.12–−0.32) 0.001
10.0 versus 12.5 −0.27 (−1.60–1.06) 0.65 −0.25 (−1.17–0.66) 0.54
last cycle endometrial measurements were compared using
ap a i r e dt-test. There was no diﬀerence in these measure-
ments (initial thickness = 8.47, ﬁnal thickness = 8.20; P>
0.1). Thus, there is no evidence that endometrial thickness
will decrease with multiple cycles of high-dose letrozole.
3.2. Eﬀect of Diagnosis on Outcome with High-Dose Letrozole.
Since the treatment goal diﬀers in women with ovulation
dysfunction(1-2 ovulations) versuswomenundergoing con-
trolled ovarian hyperstimulation with other diagnoses (2-3
ovulations or more), these groups were separated and com-
pared (Table 2)[ 8].
For the anovulatory group treated with 12.5mg/day, the
mean number of predicted ovulations was 1.88. Regression
analysis revealed BMI to have a negative eﬀect upon pre-
dicted ovulation number (P = 0.049). The overall pregnancy
rate in this group was 11%.
For the patients undergoing controlled ovarian hyper-
stimulation at this dose, the mean number of predicted ovu-
lations was 2.03. This did not diﬀer signiﬁcantly from the
anovulatory group. Regression analysis demonstrated BMI
to have an inverse eﬀect upon predicted ovulation number
(P = 0.012) as did age (P = 0.062). The overall pregnancy
rate in this group was 6%, signiﬁcantly less than that of the
patients with anovulatory cycles (P = 0.04).
3.3. Matched Pair Dose Comparison. A number of patients
were treated with diﬀerent doses of letrozole in multiple
treatment cycles. In these matched pairs, lower doses (5,
7.5,and10mg/day)werecomparedto12.5mg/day(Table 3).
Endometrial thickness did not vary signiﬁcantly with any
dose comparison, with 5mg dosing producing a scant
0.47mm thicker endometrium than 12.5mg daily. However,
there was a signiﬁcant diﬀerence in predicted ovulation
number, with all three other dosing groups producing
fewer ovulations than the 12.5mg group, and statistical
signiﬁcance was reached comparing 7.5mg versus 12.5mg
(P = 0.001).
4. Discussion
Letrozole has become an important tool in our armamen-
tarium for treating infertility, yet surprisingly little eﬀort
has been devoted toward optimizing its eﬀectiveness. The
initial dosage schedule was extrapolated from that used with
clomiphene, that is, 5 consecutive days beginning early in the
follicular phase. The dosage range was chosen based upon
estradiol suppression data from postmenopausal women.
The latter subject is of concern in that there is hesitance on
the part of physicians to explore higher doses of the drug. It
may be that the use of higher doses than those commonly
prescribed, especially in women who respond inadequately
to standard doses, will allow more patients to remain on oral
medications and not have to resort to gonadotropin therapy
or in vitro fertilization.
Available evidence suggests a dose-response with letro-
zole, with higher doses producing more mature follicles and
higherovulation rates [9].In theinitial suchstudy, 5mg daily
produced a higher number of ovulations than 2.5mg [10]. A
secondstudy,comparing2.5mg,5mg,and7.5mg,foundthe
number of mature follicles to be signiﬁcantly greater as the
dose increased (1.0, 1.4, and 3.4, resp.) [11].
This study suggests that there may be utility in increasing
the dose even further, beyond 7.5mg/day to as much as
12.5mg/day. Predicted ovulation number was greater for
increasing doses of the drug, and endometrial thickness was
unaﬀected. Thus, when the patient’s goal for number of
predicted ovulations is not met with lower doses of the drug,
it seems reasonable to explore their response to a dosage of
10–12.5mg daily.
Justiﬁcation for not exceeding doses of 2.5–7.5mg has
been based on the concept that these doses reduce estradiol
levels 88–98% [12]. However, these data, derived from post-
menopausal breast cancer patients, may not be applicable
to reproductive age women, especially those with elevated
estrogen levels due to chronic anovulation and excessive
BMI. Furthermore, at a dose of 2.5mg daily, it takes 2–4 days
for maximal suppression to occur [13]. Steady-state plasma
levelsdonotoccurforaslongas2months[14].Thus,thereis
reason to believe that higher-dose short-term administration
may be more eﬀective at inducing endogenous FSH release,
resulting in greater follicular development.
In addition, estradiol suppression may not be the only
eﬀect of value. Letrozole has been noted to inhibit other
aspectsofthesteroidogenicpathway,includingareductionin
synthesis along the cortisol pathway [4]. Thus, intraovarian
androgen accumulation may be disproportionately greater
than the reduction in estrogen. Androgen has been well
demonstrated in the primate to stimulate early follicular
growth by augmenting follicular FSH expression and to
stimulateendocrineandparacrinefactorsthatsynergizewith
FSH to promote folliculogenesis [15–21].
5. Summary
We have shown that letrozole, used in doses greater than
those commonly employed, can produce enhanced follicular
growth without detrimental eﬀects upon the endometrium.
Further study is clearly needed, including basic investigation
into estradiol and androgen levels with these doses in4 ISRN Obstetrics and Gynecology
reproductive age women. Nevertheless, we believe that high
doses of this drug can and should be employed, particularly
in women inadequately responsive to lower doses. In addi-
tion, we believe randomized trials comparing high-dose to
low-dose administration would help determine the optimal
starting dose for this medication in women of varying
diagnoses.
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